Akers Biosciences Completes Clinical Trial for Rapid Chlamydia Test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Akers Biosciences (AKER) Shares Pop Higher Upon Completion of PIFA/Chlamydia Rapid Assay Clinical Trial
June 30, 2016 9:00 AM EDTAkers Biosciences (Nasdaq: AKER) shares are popping higher in early trading after the company announced that it completed a clinical trial of its PIFA/Chlamydia Rapid Assay, the first rapid test for Chlamydia diagnosis using a finger stick blood sample.
Akers is up over 17 percent ahead of the opening bell.
... More